Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Stock Market News for December 27, 2016

Major U.S. benchmarks ended the last trading session ahead of Christmas holiday on a positive note as investors continued to cheer Trump's promises.

    Ironwood, Allergan Report Positive Linzess IBS-C Study Data

    Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.

      Arpita Dutt headshot

      Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe

      J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.

        Allergan to Buy LifeCell to Boost Regenerative Medicine Suite

        Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

          Biogen Names Commercial Officer as New CEO, Shares Fall

          Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.

            Arpita Dutt headshot

            Should Biotech Investors Worry About Donald Trump?

            It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

              Teva Copaxone EU Label to Omit Pregnancy Contraindication

              Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.

                Ryan McQueeney headshot

                Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today

                Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.

                  Amgen/Allergan File for EU Approval of Avastin Biosimilar

                  Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                    The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

                    The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

                      Company News for November 03, 2016

                      Companies In The News are: GILD,AGN,CLX,EL

                        Eric Dutram headshot

                        Your Two Minute Earnings Preview for Allergan (AGN) Stock

                        It has been a tough run for Allergan thanks to broader sector woes which have punished companies across the industry. But, can AGN turn things around in its report later this week?

                          5 Healthcare Stocks Poised to Trump Q3 Earnings

                          Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.

                            Stock Market News for September 21, 2016

                            Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today

                              Mark Vickery headshot

                              Bayer Finally Buys Monsanto, Inflation Vanishes

                              The agribusiness giant has agreed to be purchased by the German Big Pharma staple for $66 billion, and Import/Export prices swing to negative territory.

                                Stock Market News for August 09, 2016

                                Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks

                                  Stock Market News for June 16, 2016

                                  Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year

                                    Stock Market News for May 10, 2016

                                    Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks

                                      Stock Market News for April 12, 2016

                                      Benchmarks closed in the red on Monday following losses in healthcare and consumer staples stocks.

                                        Stock Market News for April 07, 2016

                                        Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks

                                          Stock Market News for March 16, 2016

                                          Benchmarks ended mostly in the red following losses in healthcare and biotech stocks. Further, continuing decline in oil prices also weighed on key U.S. indexes

                                            Arpita Dutt headshot

                                            Pharma Industry Outlook: Pricing Pressure and M&As in Focus

                                            According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.

                                              Arpita Dutt headshot

                                              Pharma Industry Outlook: Pricing Pressure and M&As in Focus

                                              According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.

                                                Kevin Cook headshot

                                                Valeant Pharma Autopsy: Counting the Lost Billions

                                                10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Outlook - July 2015

                                                  Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.